
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
About 9 percent of the U.S. population is affected by atopic dermatitis, and that percentage is growing according to the American Academy of Allergy, Asthma and Immunology (AAAAI).